Pharsight

Nocdurna patents expiration

NOCDURNA's oppositions filed in EPO
NOCDURNA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220747 FERRING PHARMS INC Methods using desmopressin acetate in orodispersible form
May, 2023

(1 year, 1 month ago)

US9504647 FERRING PHARMS INC Pharmaceutical formulations of desmopressin
May, 2023

(1 year, 1 month ago)

US10307459 FERRING PHARMS INC Pharmaceutical formulations of desmopressin
May, 2023

(1 year, 1 month ago)

US9919025 FERRING PHARMS INC Pharmaceutical formulations of desmopressin
May, 2023

(1 year, 1 month ago)

US7947654 FERRING PHARMS INC Pharmaceutical formulations
Dec, 2023

(5 months ago)

US8802624 FERRING PHARMS INC Methods of treatment using orodispersible desmopressin pharmaceutical formulations
Dec, 2023

(5 months ago)

US7560429 FERRING PHARMS INC Orodispersible dosage forms of desmopressin acetate
Feb, 2024

(4 months ago)

US10137167 FERRING PHARMS INC Methods comprising desmopressin
May, 2029

(4 years from now)

US11020448 FERRING PHARMS INC Methods comprising desmopressin
May, 2029

(4 years from now)

US9974826 FERRING PHARMS INC Methods comprising desmopressin
Apr, 2030

(5 years from now)

Nocdurna is owned by Ferring Pharms Inc.

Nocdurna contains Desmopressin Acetate.

Nocdurna has a total of 10 drug patents out of which 7 drug patents have expired.

Expired drug patents of Nocdurna are:

  • US9220747
  • US9504647
  • US10307459
  • US9919025
  • US7947654
  • US8802624
  • US7560429

Nocdurna was authorised for market use on 21 June, 2018.

Nocdurna is available in tablet;sublingual dosage forms.

Nocdurna can be used as treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration, treatment of nocturia due to nocturnal polyuria in adults.

The generics of Nocdurna are possible to be released after 13 April, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 21, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 21 June, 2018

Treatment: Treatment of nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

NOCDURNA family patents

Family Patents